These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17580150)

  • 1. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy.
    Liu M; Zhang W; Gu M; Yin C; Zhang WY; Lv Q; Xu D
    Transplant Proc; 2007 Jun; 39(5):1410-5. PubMed ID: 17580150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin is less fibrogenic than Cyclosporin A as demonstrated in a rat model of chronic allograft nephropathy.
    Luo L; Sun Z; Luo G
    J Surg Res; 2013 Jan; 179(1):e255-63. PubMed ID: 22480837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.
    Stallone G; Infante B; Schena A; Battaglia M; Ditonno P; Loverre A; Gesualdo L; Schena FP; Grandaliano G
    J Am Soc Nephrol; 2005 Dec; 16(12):3755-62. PubMed ID: 16236802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Ruiz JC; Campistol JM; Mota A; Prats D; Gutiérrez JA; Castro A; García J; Morales JM; Grynió JM; Gómez JM; Arias M
    Transplant Proc; 2003 Aug; 35(5):1669-70. PubMed ID: 12962750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy.
    Sumethkul V; Changsirikulchai S; Lothuvachai T; Chalermsanyakorn P
    Transplant Proc; 2006 Dec; 38(10):3470-2. PubMed ID: 17175307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
    Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
    Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy.
    Chen J; Li L; Wen J; Tang Z; Ji S; Sha G; Cheng Z; Sun Q; Cheng D; Liu Z
    Transplant Proc; 2008 Jun; 40(5):1411-5. PubMed ID: 18589119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity.
    Shihab FS; Bennett WM; Yi H; Andoh TF
    Am J Nephrol; 2006; 26(4):400-7. PubMed ID: 16926534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
    Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.